A Randomized Double-Blinded, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Omalizumab (Primary) ; Epinephrine
- Indications Anaphylaxis
- Focus Therapeutic Use
- 27 Nov 2020 New trial record
- 18 Nov 2020 Primary endpoint The primary objective of this study is to determine if treatment with omalizumab over 6 months will produce a reduction in the number and timing of anaphylactic events in subjects with a history of frequent idiopathic anaphylaxis has not been met as per results published in the Journal of Allergy and Clinical Immunology
- 18 Nov 2020 Results published in the Journal of Allergy and Clinical Immunology